MANGOGEN PHARMA

DEVELOPING TOMORROW'S IDEAS TODAY

Overview

MangoGen is a biopharmaceutical company with a mission to develop and market novel stents for human health. MangoGen was co-founded in 2014 by Professor Satya Prakash, Dr Paul Plested, Dr. Dominique Shum-Tim and Dr Arghya Paul.

The opportunity to develop a new bio-therapeutic stent is clearly apparent and the major stakeholders in the vascular stent market are looking for the following:

     # An effective stent that exhibits no ISR re-stenosis over time [Patients]

     # Viable to provide cost effective and safe long-term healthcare [Governments]

     # Confidence and efficacy of the product [Clinical Practitioners]

The future of the stent market is being driven towards inexpensive devices that have long-term efficacy, a lower requirement for prescribed anti-coagulants and a reduced need for future invasive cardiac surgery. MangoGen’s patented technology utilizes a novel approach of using baculovirus encapsulated in a biodegradable nanoparticle that is a adhered to a cardiac stent before being placed in situ.

Executive Team

Professor Satya Prakash PhD

President and Co-Founder

Dr. Prakash is a professor of biomedical engineering at McGill University, QC, Canada. Dr. Prakash leads a research team dedicated to the advancement and development of bioengineered delivery systems, including targeted controlled-release, targeted drug systems and cell delivery mechanisms. The goal is to design biotherapeutics that are capable of targeting specific cell types, organs or tissues to treat specific medical conditions. Dr. Prakash has had over 150 scientific publications, and 60 approved/pending patent applications. In 2003, Dr. Prakash co-founded Micropharma, a microbiome company based in Montreal, Canada. As Director of Micropharma, Prakash has taken scientific discovery through and into the commercial world. Dr. Prakash, is a co-inventor of MangoGen’s patented technology.  

C. Paul Plested D.Phil (Oxford)

CEO and Co-Founder

In 1998, Dr. Plested obtained his PhD in neuroscience from University of Oxford. Working as a post-doctoral investigator at the University of Oxford, and as a staff scientist at the Children’s Hospital of Oakland Research Institute (CHORI), California, Dr. Plested has gained a broad medical knowledge that includes cardiovascular disease, neuroscience, human parturition, oncology, vaccinology, and parasitology. Dr. Plested has had 16 scientific publications and a patent application. In 2010, Dr. Plested established his own successful communication business venture, Noviatrica, where he acted as a consultant to GSK, Mirati, HIT Global, Tactus Scientific and McGill University.  

Dr. Dominique Shum-Tim., MD., MSc., FRCSC

Chief Medical Officer and Co-Founder

Dr. Shum-Tim is a professor at the department of surgery at McGill University and a practicing cardiothoracic surgeon in the at the McGill University Health Centre (MUHC), Montreal. Dr. Shum-Tim was trained at McGill University and Harvard Medical School, Children’s Hospital, Boston. He specializes in both pediatric and adult cardiac surgery, and maintains an active research interest in cerebral protection during cardiac surgery, tissue engineering and stem cell myocardial regeneration. Dr. Shum-Tim is a co-inventor of MangoGen’s patented technology.  

Dr. Arghya Paul

Chief Scientific Officer

Dr. Arghya Paul completed his PhD (Biomedical Engineering) in Dr. Prakash’s laboratory at McGill University. After postdoctoral research at Harvard-MIT Division of Health Sciences and Technology and The Wyss Institute for Biologically Inspired Engineering at Harvard University, Dr Paul is now an assistant professor and director of the BioIntel Research Laboratory in the Department of Chemical and Petroleum Engineering, at the University of Kansas (KU). Dr Paul has received a number of prestigious awards – including the Banting Postdoctoral Fellowship, Alexander Graham Bell Graduate Scholarship, Leslie Geddes Prize in Biomedical Engineering. Dr Paul is a co-inventor of MangoGen’s patented technology.  

Proof-of-Concept

Genetic Modulation of Baculoviral DNA

First, baculoviruses were genetically modified to express a human gene (Vegf) [see Fig.1]

  bacolo schematic copy

Fig.1 Schematic illustration of genetically-modification of baculoviruses

 

Efficacy of viral transfection and entry into human cells was demonstrated in vitro using human vascular cells. Expression of Vegf protein was determined using immunocytochemistry (Fig.2).

 

VEGF vacular cells

Fig.2 Human vascular cell transfected with baculovirus expressing Vegf gen

Encapsulation and Adherence of Nanoparticles to Stent

Baculoviruses were then encapsulated in PGLA nanospheres (here). In vitro techniques were used to demonstrate that the nanoparticles housing the genetically modified baculovirus were:

i) biodegradable,

ii) viral transfection was preserved, and

iii) Vegf protein expression was maintained after encapsulation.

After viability of encapsulation methodology,  nanoparticles were then adhered to a bare metal stent. [Fig.3]

 

electron micrograph

Fig.3 Micrograph showing nanoparticle adhesion to stent surface

Proof-of-Concept Animal Model

To show proof-of-concept in vivo, stents coated with nanoparticles housing genetically-modified baculovirus were placed into balloon-damaged canine femoral arteries (Fig.4). The baculo/Vegf-stent induced a significant reduction of neointima formation and vessel stenosis, when compared to controls (Paul et al., 2013). Thus, the baculo/Vegf-stent significantly enhanced endothelial recovery (re-endothelialization) at the injured site.

artery copy jpg

Fig.4 Balloon catheter placed in a canine femoral artery

 
 
 
 
 
These findings demonstrate the potential of this newly developed baculovirus-based biotherapeutic stent to ameliorate damaged vascular biology and diminish re-narrowing (ISR) of a blood vessel stent by inhibiting neointima formation.
Paul, A., Elias, C.B., Shum-Tim D., & Prakash, A. (2013) Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization. Nature Scientific Reports 3, 2366

Publications

 

 Paul A, Hasan A, Rodes L, Sangaralingam M and Prakash S (2014) Bioengineered baculoviruses as new class of therapeutics using micro and nanotechnologies: principles, prospects and challenges. Adv Drug Rev 71, 115-30 (Pubmed)

Paul A, Elias CB, Shum-Tim D, and Prakash S. (2013) Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization. Sci Reports 3, 2366 (pdf)

Paul A, Shum-Tim D, Prakash S. (2013) Angiogenic nanodelivery systems for myocardial therapy. Methods Mol Biol. 1036, 137-49 (Pubmed)

 Binsalamah ZM, Paul A, Prakash S, Shum-Tim D.(2012) Nanomedicine in cardiovascular therapy: recent advancements. Expert Rev Cardiovasc Ther. 10(6), 805-15 (Pubmed)

Paul A, Shao W, Shum-Tim D, Prakash S. (21012) The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNA(Ang1+Vegf) nanoparticles. Biomaterials. 33(30):7655-64 (Pubmed)

Paul A, Shao W, Abbasi S, Shum-Tim D, Prakash S. (2012) PAMAM dendrimer-baculovirus nanocomplex for microencapsulated adipose stem cell-gene therapy: in vitro and in vivo functional assessment. Mol Pharm. 9(9), 2479-88 (Pubmed)

Jardin BA, Elias CB, Prakash S. (2012) Expression of a secreted protein in mammalian cells using baculovirus particles. Methods Mol Biol. 801, 41-63 (Pubmed)

 Binsalamah ZM, Paul A, Khan AA, Prakash S, Shum-Tim D. 2011) Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model. Int J Nanomedicine. 6, 2667-78 (pdf)

 Paul A, Binsalamah ZM, Khan AA, Abbasia S, Elias CB, Shum-Tim D, Prakash S. (2011) A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. Biomaterials. 32(32), 8304-18 (Pubmed)

 Prakash S, Malhotra M, Shao W, Tomaro-Duchesneau C, Abbasi S. (2011) Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Adv Drug Deliv Rev. 6, 1340-51 (Pubmed)

 Khan AA, Paul A, Abbasi S, Prakash S. (2011) Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells. Int J Nanomedicine. 6, 1069-81 (pdf)

 Malhotra M, Lane C, Tomaro-Duchesneau C, Saha S, Prakash S. (2011) A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis. Int J Nanomedicine. 6, 485-94 (pdf)

Paul A, Elhayek E, Shum-Tim D, Prakash S. (2010) Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges. Curr Drug Deliv. 2010 May 24 (Pubmed)

 

cropped-large-logo.jpeg2015

Investment Information

 

Investors

 

MangoGen Pharma Inc. is a biotherapeutic company with a mission to develop novel approaches to deliver specific gene therapy for the treatment of wound healing. Our proof-of-concept has shown that our approach can accelerate the re-endothelialization around a stent site, reducing the risk of  re-stenosis.  The potential outcomes of this approach are improved patient outcome, and significant socioeconomic savings.

 

The MangoGen team is dedicated to developing and producing this novel stent.

 

If you are interested in investment opportunities, please contact:

 

Paul Plested CEO

 

 

invest@mangogen.com

Executive Team

Professor Satya Prakash PhD

President and Co-Founder

Dr. Prakash is a professor of biomedical engineering at McGill University, QC, Canada. Dr. Prakash leads a research team dedicated to the advancement and development of bioengineered delivery systems, including targeted controlled-release, targeted drug systems and cell delivery mechanisms. The goal is to design biotherapeutics that are capable of targeting specific cell types, organs or tissues to treat specific medical conditions. Dr. Prakash has had over 150 scientific publications, and 60 approved/pending patent applications. In 2003, Dr. Prakash co-founded Micropharma, a microbiome company based in Montreal, Canada. As Director of Micropharma, Prakash has taken scientific discovery through and into the commercial world. Dr. Prakash, is a co-inventor of MangoGen’s patented technology.  

C. Paul Plested D.Phil (Oxford)

CEO and Co-Founder

In 1998, Dr. Plested obtained his PhD in neuroscience from University of Oxford. Working as a post-doctoral investigator at the University of Oxford, and as a staff scientist at the Children’s Hospital of Oakland Research Institute (CHORI), California, Dr. Plested has gained a broad medical knowledge that includes cardiovascular disease, neuroscience, human parturition, oncology, vaccinology, and parasitology. Dr. Plested has had 16 scientific publications and a patent application. In 2010, Dr. Plested established his own successful communication business venture, Noviatrica, where he acted as a consultant to GSK, Mirati, HIT Global, Tactus Scientific and McGill University.  

Dr. Dominique Shum-Tim., MD., MSc., FRCSC

Chief Medical Officer and Co-Founder

Dr. Shum-Tim is a professor at the department of surgery at McGill University and a practicing cardiothoracic surgeon in the at the McGill University Health Centre (MUHC), Montreal. Dr. Shum-Tim was trained at McGill University and Harvard Medical School, Children’s Hospital, Boston. He specializes in both pediatric and adult cardiac surgery, and maintains an active research interest in cerebral protection during cardiac surgery, tissue engineering and stem cell myocardial regeneration. Dr. Shum-Tim is a co-inventor of MangoGen’s patented technology.  

Dr. Arghya Paul

Chief Scientific Officer

Dr. Arghya Paul completed his PhD (Biomedical Engineering) in Dr. Prakash’s laboratory at McGill University. After postdoctoral research at Harvard-MIT Division of Health Sciences and Technology and The Wyss Institute for Biologically Inspired Engineering at Harvard University, Dr Paul is now an assistant professor and director of the BioIntel Research Laboratory in the Department of Chemical and Petroleum Engineering, at the University of Kansas (KU). Dr Paul has received a number of prestigious awards – including the Banting Postdoctoral Fellowship, Alexander Graham Bell Graduate Scholarship, Leslie Geddes Prize in Biomedical Engineering. Dr Paul is a co-inventor of MangoGen’s patented technology.  

Contact Us

large logo MangoGen Pharma Inc.

Suite 114

500 Cartier West Blvd.,

Laval

Québec

H7V 5B7

Tel:  +1-514-800-6872

E-mail: admin@mangogen.com

www.mangogen.com

On the Map

CLICK HERE for Directions

Careers @ MangoGen

If interested in joining MangoGen Pharma please contact   careers@mangogen.com  

We are on